Cost-minimization and budget impact analysis of certolizumab pegol for patients with Crohn's disease, moderate or severe, with relapse after conventional treatment from the perspective of the Brazilian private payer

Rosim, Ricardo Papaléo; Duva, Andreas de Souza; Ferraz, André Fabre Ballalai; Valle, Arcangela; Tóth, Emese; Ferguson, Samara; Carmo, Érico V. S.
J. bras. econ. saúde (Impr.); 9(1): http://www.jbes.com.br/images/v9n1/44.pdf, Abril, 2017.
Artigo em Inglês | ECOS | ID: biblio-833560